-
Study Shows Proof of Concept of BioIVT HEPATOPAC Cultures with Targeted Assay to Evaluate Bioactivation Potential and Drug-induced Liver Injury (DILI) Risk
Oct 12, 2020, 08:14 AM by Abhinav SinghWESTBURY, NY - Oct 12, 2020 - BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI)Full story -
The Great Data Science Promise For COVID-19, Opioid Addiction
Oct 12, 2020, 02:15 AM by Michael CroftBio-IT World | The Bio-IT World Conference & Expo Virtual launched last week with an opening plenary keynote from Drs. Susan Gregurick, Associate Director for Data Science at NIH and Rebecca Baker, Director of the HEAL Initiative at NIH.Full story -
Alfa Chemistry Materials Offers Wide Options of Resins for Decoration or Manufacture of Plastics
Oct 10, 2020, 01:53 AM by Abhinav SinghNY, NY - Oct 10, 2020 - On October 8, 2020, Alfa Chemistry Materials announces to provide wide options of resins for customers worldwide, which have broad applications in decoration, manufacture of plastics as well as other fieldsFull story -
Novel T Cell Subset, Nitric Oxide Effective Treatment Option, SoCal cases linked to New York: COVID-19 Updates
Oct 9, 2020, 04:50 AM by Michael CroftBio-IT World | MIT’s preprint reviewers debunk synthetic SARS-CoV-2 paper, genetic analysis of virus samples show most COVID-19 cases in Southern California early in the pandemic are linked to New York state via Europe, not directly from China, vaccines should not be affected by the dominant ‘G-strain’, severe cases of COVID-19 develop a novel T cell subset that can potentially kill B cells, and MS drug inhibits virus growth. Plus, NIH funds COVID-10 vaccine using bovine adenovirus.Full story -
Abzena invests $60m into cGMP manufacturing capacity
Oct 8, 2020, 15:15 PM by Abhinav SinghSAN DIEGO, CA, UNITED KINGDOM - Oct 8, 2020 - Leading contract provider of integrated discovery, development and manufacturing services for biologics and bioconjugates, Abzena, has invested $60m into a new facility for late phase and commercial cGMP manufacturingFull story -
Bio-IT World Virtual: Gamifying Discovery, Human-in-the-Loop AI, New Data Commons Model
Oct 7, 2020, 19:00 PM by Michael CroftBio-IT World Day two of the Bio-IT World Conference & Expo Virtual was highlighted by a plenary keynote on artificial intelligence (AI) and citizen science, a new data commons maturity model, guidance for FAIRifying data, augmented intelligence systems for biological data, and much more.Full story -
Solentim to supply cell line development solutions for Samsung Biologics’ new R&D center in San Francisco
Oct 7, 2020, 05:07 AM by Michael CroftBOURNEMOUTH, UNITED KINGDOM - Oct 7, 2020 - Solentim is pleased to announce the adoption of its VIPS single cell seeding platform and Cell Metric® CLD into Samsung Biologics new research and development facility in San Francisco, CAFull story -
Sandia helps safeguard biological data threatened during COVID-19 pandemic
Oct 7, 2020, 02:10 AM by Michael CroftCAMBRIDGE, UNITED KINGDOM - Oct 6, 2020 - A partnership between Sandia National Laboratories and the Boston firm BioBright LLC to improve the security of synthetic biology equipment has become more relevant after the United States and others issued warnings that hackers were using the COVID-19 pandemic to increase their activitiesFull story -
Bio-IT World Virtual: First Plenary, AI Workshops, Globus For Data Transfer
Oct 6, 2020, 19:15 PM by Michael CroftBio-IT World The Bio-IT World Conference & Expo Virtual launched today with an open plenary keynote from Drs. Susan Gregurick, Associate Director for Data Science at NIH and Rebecca Baker, Director of the HEAL Initiative at NIH. The rest of the day was full of workshops covering AI in clinical trials and drug discovery, tools for moving data quickly and safely, wearables to gather data, and much more.Full story -
NVIDIA and PetaGene Combine Genomic Technologies to Address Critical Analysis Bottlenecks
Oct 6, 2020, 17:15 PM by Michael CroftCAMBRIDGE, UK - Oct 6, 2020 - PetaGene and NVIDIA announce seamless integration of PetaGene's PetaSuite tools as a standard part of NVIDIA Clara Parabricks PipelinesxFull story -
TrialScope Adds Eisai to Its Community of Study Sponsors
Oct 6, 2020, 13:08 PM by Michael CroftJERSEY CITY, NJ, US - Oct 6, 2020 - TrialScope, the global leader in clinical trial disclosure and transparency management technology, has added a new study sponsor to its growing customer rosterFull story -
InSysBio to release the new version of DBSolve Optimum
Oct 6, 2020, 09:57 AM by Michael CroftMOSCOW, RUSSIA - Oct 6, 2020 - InSysBio, one of the worlds pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases the new version of mathematical simulation workbench DBSolveOptimum 2020Full story -
Sterling Pharma Solutions launches £11 million Material Science Centre
Oct 6, 2020, 04:53 AM by Michael Croft- Sep 27, 2020 - Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has officially opened its new multi-million-pound Material Science Centre (MSC), after announcing the investment last yearFull story -
10x Genomics Announces Two In Situ Sequencing Acquisitions
Oct 5, 2020, 19:05 PM by Michael CroftBio-IT World 10x Genomics today announced its second in situ sequencing acquisition: Boston-based ReadCoor, Inc. for cash and stock consideration of $350 million. In late August, 10x Genomics’ acquired Stockholm-based Cartana, developers of in situ RNA analysis technology.Full story -
Abzena appoints Giovanni Escobar as SVP and Site Head of Bristol, Pennsylvania Operations
Oct 5, 2020, 13:32 PM by Michael CroftCAMBRIDGE, UNITED KINGDOM - Oct 5, 2020 - Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Giovanni Escobar as Senior Vice President (SVP) and Site Head of its Bristol OperationsFull story -
VERICHEM LABORATORIES OFFERS LIQUID STABLE, READY-TO-USE, MULTI-ANALYTE ELECTROLYTE STANDARD KIT
Oct 5, 2020, 10:01 AM by Michael CroftPROVIDENCE, RI, UNITED STATES - Oct 5, 2020 - VERICHEM LABORATORIES is pleased to announce the availability of a ready-to-use, liquid stable Electrolyte Standard KitFull story -
Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates
Oct 2, 2020, 10:40 AM by Michael CroftBio-IT World | Genetic variations not driving outcomes, bio-sensing viral translation, pursuit of a passive vaccine, an Android app that analyzes the SARS-CoV-2 genome, potential antibody cocktails, targeting the hairpin, spike protein may be superantigen, implicating MAIT cells, three mutations common to COVID cases in the U.S., naturally occurring lipid and enzyme hold promise, research using breathing human lungs cells, widespread preexisting immunity, and a Neandertal gene variant that triples the risk of severe disease. Plus, an interactive exhibition about COVID-19 and an international team of experts will study how viral diseases "spill over" from animals to humans.Full story -
A Computational Approach to Modeling COVID-19
Oct 2, 2020, 10:10 AM by Michael CroftFull storyBio-IT World | In months since March, the biotech community has rallied to identify how our unique perspectives and skills can help with the COVID-19 pandemic. The computational biologists at QuartzBio were no different. Although the research team wasn’t generating their own COVID-19 data, the collaborative culture was generating and sharing raw data to play with, so the QuartzBio team began building models.
-
Panthera Biopartners concludes Series A financing with Gresham House Ventures as major investor
Oct 2, 2020, 09:26 AM by Michael CroftPRESTON, UNITED KINGDOM - Oct 2, 2020 - Panthera Biopartners (Panthera) has completed a Series A funding round with Gresham House Ventures as a major investorFull story -
A vulnerability in IBM Maximo asset management system, discovered by Positive Technologies, was fixed
Oct 1, 2020, 11:25 AM by Michael CroftFRAMINGHAM, MA, UNITED STATES - Oct 1, 2020 - Framingham, MA (October 1, 2020) -- A vulnerability in IBM Maximo Asset Management software was discovered by Positive Technologies experts Andrey Medov and Arseny SharoglazovFull story